ARCA biopharma Inc (ABIO)
2.08
+0.05
(+2.46%)
USD |
NASDAQ |
Mar 24, 16:00
2.02
-0.06
(-2.88%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 29.11M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -16.29% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.6985 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.78% |
News
Headline
Wire
Time (ET)
Yahoo
02/03 10:19
MT Newswires
10/14 09:20
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/02/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 10/28/2022 | -- | Results | Q3 2022 | -- | -- | -- | |
| 08/02/2022 | -- | Results | Q2 2022 | -- | -- | -- | |
| 05/02/2022 | -- | Results | Q1 2022 | -- | -- | -- | |
| 03/14/2022 | -- | Results | Q4 2021 | -- | -- | -- | |
| 11/02/2021 | -- | Results | Q3 2021 | -- | -2.30 | -- | |
| 08/04/2021 | -- | Results | Q2 2021 | -- | -2.37 | -- | |
| 05/11/2021 | -- | Results | Q1 2021 | -- | -1.87 | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |
| URL | http://www.arcabiopharma.com |
| Investor Relations URL | http://arcabio.com/investors/ |
| HQ State/Province | Colorado |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 02, 2023 (est.) |
| Last Earnings Release | Oct. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 10.60M |
| Net Income (TTM) | -9.926M |
| Total Assets (Quarterly) | 43.08M |
| Total Liabilities (Quarterly) | 1.412M |
| Shareholders Equity (Quarterly) | 41.67M |
| Cash from Operations (TTM) | -10.91M |
| Cash from Investing (TTM) | -0.002M |
| Cash from Financing (TTM) | 0.00 |
Ratings
Profile
Edit
| ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |
| URL | http://www.arcabiopharma.com |
| Investor Relations URL | http://arcabio.com/investors/ |
| HQ State/Province | Colorado |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 02, 2023 (est.) |
| Last Earnings Release | Oct. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ABIO Tweets |